Silexion Therapeutics Corp Operating Income 2021-2024 | SLXN

Silexion Therapeutics Corp operating income from 2021 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Silexion Therapeutics Corp Operating Income 2021-2024 | SLXN

Silexion Therapeutics Corp operating income from 2021 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$180.1B
Regeneron Pharmaceuticals (REGN)$127.1B
Vertex Pharmaceuticals (VRTX)$126.3B
Gilead Sciences (GILD)$103.5B
Bristol Myers Squibb (BMY)$101.3B
CSL (CSLLY)$97.4B
GSK (GSK)$90.3B
Alnylam Pharmaceuticals (ALNY)$34.7B
Argenex SE (ARGX)$32.2B
BioNTech SE (BNTX)$29.4B
Biogen (BIIB)$29.1B
Moderna (MRNA)$26.6B
Illumina (ILMN)$20.6B
BeiGene (BGNE)$19.1B
Genmab (GMAB)$17.6B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.8B
Incyte (INCY)$12.8B
Vaxcyte (PCVX)$12.8B
Insmed (INSM)$12.6B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.6B
Legend Biotech (LEGN)$9.4B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.1B
Halozyme Therapeutics (HALO)$8B
Intra-Cellular Therapies (ITCI)$8B
Repligen (RGEN)$7.8B